Q-omics provides the consensus-scored ZNF594 profile across patient tissues and cancer cell-line models. ZNF594 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZNF594 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, ZNF594 RNA expression shows 21,087 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, THCA, and THYM as cancer lineages where ZNF594 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF594 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF594 survival associations across molecular data types. ZNF594 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF594 RNA expression–survival associations across cancer types. High ZNF594 expression shows unfavorable associations in MESO and COAD, but favorable associations in HNSC, PAAD, KIRC and READ. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZNF594 RNA expression.
This table summarizes ZNF594 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF594. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF594 shows lower tumor expression in THCA, KICH and KIRC and higher tumor expression in HNSC, CHOL and LUSC. The THCA box plot shows higher ZNF594 RNA expression in normal versus tumor tissue (log2 FC = −1.162, t-test p < 0.001).
This table shows molecular features associated with ZNF594 in patient tissues and cancer cell lines. In patient samples, ZNF594 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF594 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
